Literature DB >> 20871690

"Off-label" indications for oncology drug use and drug compendia: history and current status.

.   

Abstract

Year:  2005        PMID： 20871690      PMCID： PMC2794406          DOI： 10.1200/JOP.2005.1.3.102

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  4 in total

Review 1.  Drugs of choice for cancer.

Authors: 
Journal:  Treat Guidel Med Lett       Date:  2003-03

2.  Drugs for breast cancer.

Authors: 
Journal:  Treat Guidel Med Lett       Date:  2005-01

Review 3.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

4.  Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

Authors:  D P Forward; K L Cheung; L Jackson; J F R Robertson
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640
  4 in total
  8 in total

1.  Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.

Authors:  Paul E Kalb; Paul E Greenberg
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Delivering high-quality and affordable care throughout the cancer care continuum.

Authors:  Ya-Chen Tina Shih; Patricia A Ganz; Denise Aberle; Amy Abernethy; Justin Bekelman; Otis Brawley; James S Goodwin; Jim C Hu; Deborah Schrag; Jennifer S Temel; Lowell Schnipper
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

3.  Off-label.

Authors:  John V Cox
Journal:  J Oncol Pract       Date:  2011-03       Impact factor: 3.840

Review 4.  Current challenges in health economic modeling of cancer therapies: a research inquiry.

Authors:  Jeffrey D Miller; Kathleen A Foley; Mason W Russell
Journal:  Am Health Drug Benefits       Date:  2014-05

5.  Conflict of interest disclosure in off-label oncology clinical trials.

Authors:  Blair Irwin; Bradford R Hirsch; Gregory P Samsa; Amy P Abernethy
Journal:  J Oncol Pract       Date:  2012-06-26       Impact factor: 3.840

6.  Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.

Authors:  Rhonda Greenapple
Journal:  Am Health Drug Benefits       Date:  2012-07

7.  Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China.

Authors:  Weilan Wang; Man Zhu; Daihong Guo; Chao Chen; Dongxiao Wang; Fei Pei; Liang Ma
Journal:  Iran J Public Health       Date:  2013-05-01       Impact factor: 1.429

8.  Automated detection of off-label drug use.

Authors:  Kenneth Jung; Paea LePendu; William S Chen; Srinivasan V Iyer; Ben Readhead; Joel T Dudley; Nigam H Shah
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.